NOVN - Novan, Inc.
| Previous Close | 2.51 |
| Open | 2.50 |
| Bid | 2.03 x 4000 |
| Ask | 2.99 x 800 |
| Day's Range | 2.44 - 2.60 |
| 52 Week Range | 2.44 - 7.33 |
| Volume | 27,608 |
| Avg. Volume | 37,800 |
| Market Cap | 63.795M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- American City Business Journals•9 days ago
New Novan incentive plan targets share price goals and $25M, $50M bonus pools
A newly implemented stockholder return plan at Morrisville-based Novan is targeting share price goals as well as $25 million and $50 million bonus pools.
- GlobeNewswire•10 days ago
Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
Novan, Inc. ("the Company" or "Novan") (NOVN) today provided a comprehensive business update in its Form 10-Q for the second quarter of 2018 and announced that it has implemented the Tangible Stockholder Return Plan (the “Performance Plan”). The Performance Plan is a performance-based incentive compensation plan designed to directly align the long-term interests of Novan’s employees, including executive officers, with the interests of Novan’s stockholders.
- MarketWatch•last month
Novartis had ‘longer and more detailed’ relationship with Trump lawyer Michael Cohen, Senate report finds
Novartis’ then-CEO sent ideas to lower drug prices to Michael Cohen — proposals that later appeared in President Donald Trump’s drug pricing plan.
- GlobeNewswire•2 months ago
Novan to Participate in Upcoming Investor Conferences
MORRISVILLE, N.C., June 13, 2018-- Novan, Inc. today announced that members of management are scheduled to attend the 2018 Cantor Dermatology & Aesthetics Summit and the 2018 JMP Securities Life Sciences ...
- Simply Wall St.•2 months ago
Does Novan Inc’s (NASDAQ:NOVN) Earnings Growth Make It An Outperformer?
Assessing Novan Inc’s (NASDAQ:NOVN) past track record of performance is a valuable exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...
- GlobeNewswire•3 months ago
Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Novan, Inc. ("the Company" or "Novan") (NOVN) today reported that the Compensation Committee of Novan’s Board of Directors granted stock options to purchase an aggregate of 100,500 shares of its common stock to four newly-hired employees with a grant date of May 31, 2018. The stock options were granted as inducements material to the new employees entering into employment with Novan in accordance with Nasdaq Listing Rule 5635(c)(4).
- CNBC•3 months ago
Trump attorney Cohen got about $500,000 from Russian oligarch, Stormy Daniels' lawyer claims
Michael Avenatti, the lawyer for porn star Stormy Daniels, claimed Tuesday that President Donald Trump's personal attorney Michael Cohen received about $500,000 from a Russian oligarch after the 2016 presidential election. The oligarch Viktor Vekselberg, has close ties to Russian leader Vladimir Putin, and was stopped at a New York-area airport in recent months by investigators working for special counsel Robert Mueller. Cohen paid Daniels $130,000 on the eve of the election in exchange for what she says was her silence about an affair with Trump in 2006.
- American City Business Journals•4 months ago
Same as the old boss — Novan makes interim CEO permanent
Morrisville-based Novan has made its interim CEO Kelly Martin permanent, while it looks to a big third quarter for its acne drug.
- Simply Wall St.•4 months ago
Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success?
Novan Inc’s (NASDAQ:NOVN) latest earnings update in December 2017 revealed that losses became smaller relative to the prrior year’s level as a result of recent tailwinds Below, I’ve laid outRead More...
- CNBC•5 months ago
Here's what CEOs and other leaders are saying at the China Development Forum in Beijing
Major figures in business, economics and politics spoke with CNBC at the China Development Forum in Beijing on Sunday.
- GlobeNewswire•5 months ago
Novartis expands alliance with Science 37 to advance virtual clinical trials program
Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in ...
- GlobeNewswire•5 months ago
Novartis' Xolair® recommended in new global chronic urticaria guideline
Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), is the only therapy recommended by the guideline for patients unresponsive to antihistamines ...
- GlobeNewswire•6 months ago
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
Shareholders approve 21 st consecutive dividend increase to CHF 2.80 (+2%) per share for 2017; representing a 3.6% yield and approximately 67% payout of free cash flow Dr. Joerg Reinhardt confirmed by ...
- GlobeNewswire•6 months ago
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis` leadership in biomedical ...
- GlobeNewswire•6 months ago
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
Ultibro ® Breezhaler ® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to investigate the effect ...
- GlobeNewswire•6 months ago
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
Two thirds of patients on Cosentyx ® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows Findings show absolute PASI 5 Cosentyx is the ...
- GlobeNewswire•6 months ago
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
Majority of patients with scalp psoriasis on Cosentyx ® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life Scalp psoriasis affects 60 million people worldwide ...
- CNBC Videos•4 months ago
Cramer: There's always a better time to sell
Jim Cramer explains why Friday's sell-off was not the ideal time for investors to sell out of their positions.
- CNBC Videos•4 months ago
Cramer: We got too negative on Friday—there's always a be...
Jim Cramer explains why Friday's sell-off was not the ideal time for investors to sell out of their positions.
- CNBC Videos•5 months ago
Novartis CEO on Alcon and Sandoz
Vasant Narasimhan of Novartis discusses the company's plans for the two subsidiaries.
